PARP Inhibitors for Cancer Therapy
PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP—poly ADP ribose polymerase—in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discus...
| Autor Corporativo: | |
|---|---|
| Otros Autores: | , |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Cham :
Springer International Publishing
2015.
|
| Colección: | Cancer Drug Discovery and Development ;
83. Springer eBooks. |
| Acceso en línea: | Conectar con la versión electrónica |
| Ver en Universidad de Navarra: | https://innopac.unav.es/record=b30630319*spi |
Tabla de Contenidos:
- History of the discovery of poly (ADP-ribose)
- Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members
- The role of PARPs in DNA Strand Break Repair
- TIPs: Tankyrase Interacting Proteins
- PARP and Carcinogenesis
- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity
- Overview of PARP Inhibitor Design and Optimization
- Structure Based Design of PARP Inhibitors
- Preclinical chemosensitization by PARP inhibitors
- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents
- Radiosensitisation by poly(ADP-ribose) polymerase inhibition
- The vasoactivity of PARP inhibitors
- Synthetic lethality with Homologous Recombination Repair defects
- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality
- Other determinants of sensitivity
- Synthetic sickness with molecularly targeted agents against the EGFR pathway
- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition
- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations
- PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration
- Introduction to PARPi clinical trials and future directions
- Clinical trials investigating PARP inhibitors as single agents
- Clinical trials of PARP inhibitors with chemotherapy
- Combination of PARP inhibitors with clinical radiotherapy
- Biomarkers for PARP Inhibitors.
